Please visit our MS learning channel on YouTube, which provides hundreds of MS related topics from many of our video recorded education programs and archived here: -- Be empowered with MS views and news. Opt-in with us:

~~ Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Wednesday, May 17, 2017

Statins: How safe are they?

Click here to receive MS news via e-mail

Despite evidence that aims to quash controversy over the safety and effectiveness of statins, uncertainty remains. Is the safety of statins as debatable as some stories suggest, or is the controversy behind this group of medicines potentially harming more people than the drug itself? We find out.

[packet of statin tablets]

Cholesterol is essential to keep the body in working order. However, having high levels of "bad cholesterol," called low-density lipoprotein (LDL), in the blood can cause fatty deposits to build up in the arteries. Eventually, this buildup results in the arteries narrowing and hardening (a condition called atherosclerosis), which leads to a greater risk of heart attack and stroke.

Statins are a commonly prescribed medicine that helps to lower harmful levels of LDL cholesterol to mitigate the risks of cardiovascular disease.

MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis
MS Views and News provides beneficial information for those affected by Multiple Sclerosis.  
Join us by registering here: 

No comments: